Share This Author
Final version of 2009 AJCC melanoma staging and classification.
Revised melanoma staging system has been made that reflect the improved understanding of this disease and will be formally incorporated into the seventh edition of the AJCC Cancer Staging Manual and implemented by early 2010.
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Answer questions and earn CME/CNE
Final trial report of sentinel-node biopsy versus nodal observation in melanoma.
Biopsy-based staging of intermediate-thickness or thick primary melanomas provides important prognostic information and identifies patients with nodal metastases who may benefit from immediate complete lymphadenectomy, and prolongs disease-free survival and melanoma-specific survival.
Genomic Classification of Cutaneous Melanoma
Sentinel-node biopsy or nodal observation in melanoma.
The staging of intermediate-thickness primary melanomas according to the results of sentinel-node biopsy provides important prognostic information and identifies patients with nodal metastases whose survival can be prolonged by immediate lymphadenectomy.
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter.
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
Porphyry deposits; characteristics and origin of hypogene features
Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma
Immediate completion lymph‐node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma‐specific survival among patients with melanoma and sentinel‐node metastases.
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
The increase in tumor-infiltrating lymphocytes induced by treatment with BRAf inhibitors provides strong support for conducting trials that combine BRAF inhibitors with immunotherapy in the hope of prolonging clinical responses.